These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 1718486

  • 1. [Thymus hyperplasia after chemotherapy in a case of Hodgkin's disease].
    Andreopoulos D, Klose KC, Glöckner WM.
    Rofo; 1991 Oct; 155(4):375-6. PubMed ID: 1718486
    [No Abstract] [Full Text] [Related]

  • 2. Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease.
    Brosteanu O, Hasenclever D, Loeffler M, Diehl V, German Hodgkin's Lymphoma Study Group.
    Ann Hematol; 2004 Mar; 83(3):176-82. PubMed ID: 15064867
    [Abstract] [Full Text] [Related]

  • 3. Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis.
    Scholz M, Engert A, Franklin J, Josting A, Diehl V, Hasenclever D, Loeffler M.
    Ann Oncol; 2011 Mar; 22(3):681-688. PubMed ID: 20720088
    [Abstract] [Full Text] [Related]

  • 4. Analysis of the risk of solid tumor following Hodgkin's disease.
    Maurizi Enrici R, Anselmo AP, Osti MF, Santoro M, Tombolini V, Mandelli F, Biagini C.
    Haematologica; 1997 Mar; 82(1):57-63. PubMed ID: 9107084
    [Abstract] [Full Text] [Related]

  • 5. [Clinical analysis of reactive thymic hyperplasia following chemotherapy for childhood malignant lymphoma].
    Zhen ZJ, Sun XF, Xia Y, Wang ZH, Ling JY.
    Ai Zheng; 2006 Apr; 25(4):471-5. PubMed ID: 16613683
    [Abstract] [Full Text] [Related]

  • 6. [Diffuse thymus hyperplasia following chemotherapy for nodular sclerosing Hodgkin lymphoma].
    Hermann R, Greminger P, Dommann-Scherrer C, Krestin GP, Stahel R.
    Schweiz Med Wochenschr; 1994 Sep 24; 124(38):1666-71. PubMed ID: 7524146
    [Abstract] [Full Text] [Related]

  • 7. Chemotherapy-induced non-Hodgkin's lymphoma in a patient with Hodgkin's disease--a case report.
    Burney IA, Malik IA.
    J Pak Med Assoc; 1996 Jan 24; 46(1):14-5. PubMed ID: 8830160
    [No Abstract] [Full Text] [Related]

  • 8. Cardiopulmonary toxicity of different chemoradiotherapy combined regimens for Hodgkin's disease.
    Busia A, Laffranchi A, Viviani S, Bonfante V, Villani F.
    Anticancer Res; 2010 Oct 24; 30(10):4381-7. PubMed ID: 21036768
    [Abstract] [Full Text] [Related]

  • 9. Early intensification treatment approach in advanced-stage Hodgkin lymphoma.
    Borchmann P.
    Hematol Oncol Clin North Am; 2014 Feb 24; 28(1):65-74. PubMed ID: 24287068
    [Abstract] [Full Text] [Related]

  • 10. The early- and intermediate-term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced hodgkin lymphoma.
    Gobbi PG, Rosti V, Valentino F, Bonetti E, Merli F, Stelitano C, Dondi A, Quarta G, Falorio S, Federico M.
    Clin Lymphoma Myeloma; 2009 Dec 24; 9(6):425-9. PubMed ID: 19951881
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S, Camós M, López-Guillermo A, Bosch F, Cervantes F, Blandé J, Esteve J, Cobo F, Nomdedeu B, Campo E, Montserrat E.
    Cancer; 2000 May 01; 88(9):2142-8. PubMed ID: 10813727
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Male infertility caused by the chemotherapy of Hodgkin's disease: MOPP versus ABVD.
    Ragni G, Lombardi C, Santoro A, Bestetti O, Wyssling H.
    Acta Eur Fertil; 1983 May 01; 14(3):221-2. PubMed ID: 6199937
    [No Abstract] [Full Text] [Related]

  • 18. Third-line salvage chemotherapy in Hodgkin's disease.
    Bonadonna G, Viviani S, Valagussa P, Bonfante V, Santoro A.
    Semin Oncol; 1985 Mar 01; 12(1 Suppl 2):23-5. PubMed ID: 2579440
    [Abstract] [Full Text] [Related]

  • 19. Are ABVD and MOPP/ABV truly equivalent for treating Hodgkin's disease at advanced stages?
    Andrieu JM, Colonna P.
    J Clin Oncol; 1998 Jun 01; 16(6):2283. PubMed ID: 9626234
    [No Abstract] [Full Text] [Related]

  • 20. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
    Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, Canellos GP, Peterson BA.
    J Clin Oncol; 2003 Feb 15; 21(4):607-14. PubMed ID: 12586796
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.